What Does It Take To Launch And Lead An Oncology Biotech Today?
What Does It Take To Launch And Lead An Oncology Biotech Today?
$200.00
Oncolytic virus company Theolytics has emerged ready to raise a series A round and get its preclinical assets into human trials by 2021. CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be the answer to the cancer drug pricing conundrum. Learn what this young CEO (at age 26) has to say about the skills required to be a biotech CEO today, the concerning issue of access to novel personalized cancer treatments, and the biggest challenges she sees in cancer drug development today.
Publisher: InVivo
- Description
In this interview with In Vivo, Theolytics CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be the answer to the cancer drug pricing conundrum. As the oncolytic virus company gears up to raise a series A round and get its preclinical assets into human trials by 2021, learn what this rising CEO has to say about the dramatic changes in the R&D sector in recent years, what excites her in the oncology space in terms of development trends and innovation, and the biggest challenges she sees in cancer drug development today.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manip... 
Sign up to the